Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Glioblastoma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Solid Tumors 1Rhabdomyosarcoma 1Rectal Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1NSCLC 1Lymphoma 1Gliosarcoma 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Astrocytoma 1Advanced Tumor 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

cediranib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Tumor × Gefitinib × Clear all
NCT00502060 2009-05-14

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
65 enrolled

Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡